Fig. 8.

The secretome from activated MCs induced an iCAF phenotype. A mPSCs were treated with MC secretome of MCs pre-treated with WT- or KO-EVs. Gene expression of iCAF markers and mCAF markers was determined by RT-qPCrR. (mean ± SEM, n = 6). B UMAP projection of fibroblast markers Col1a and aSMA in WT/KO tumors. C Col1a expression in KO and WT tumors determined by RT-qPCR. Data were normalized to Rpl32 (mean ± SEM, n = 9–14). D Graphical summary of mPSC/fibroblast phenotypes in vivo or after MC secretome treatment. Statistical significance: unpaired Mann–Whitney U test; *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001